Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 16/20 | 0.76 |
| ▸ | FOLR1 | P15328 | 12/20 | 0.76 |
| ▸ | SLC46A1 | Q96NT5 | 6/20 | 0.47 |
| ▸ | SLC19A1 | P41440 | 4/20 | 0.47 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.47 |
| ▸ | ATIC | P31939 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29497776 | 0.86 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL7607137 | 0.81 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL7614066 | 0.77 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL7612357 | 0.76 | FOLR1 (0.68) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL7134514 | 0.75 | HDAC1 (0.52) | GARTFOLR1 | |
| SCHEMBL7615527 | 0.74 | GART (0.81) | GARTFOLR1SLC46A1FOLR2ATIC | |
| SCHEMBL7606988 | 0.74 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL7615531 | 0.73 | FOLR1 (0.64) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL7609290 | 0.72 | GART (0.79) | GARTFOLR1 | |
| SCHEMBL7609677 | 0.72 | GART (0.77) | GARTFOLR1ATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594900-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CANCERS | Salmedix, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040247600-A1 | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers | CEPHALON, INC. | 2004-12-09 | — | — | US | claimed |
| WO-2004074325-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CANCERS | SALMEDIX, INC (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | claimed |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-20 | — | — | US | claimed |
| WO-2004012746-A2 | NEW USES FOR INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | claimed |
| WO-2004012769-A1 | THERAPEUTIC INHIBITIONOF PROTEIN KINASES IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | claimed |
| US-7157551-B2 | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers | CEPHALON, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1594900-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CANCERS | Salmedix, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040247600-A1 | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers | CEPHALON, INC. | 2004-12-09 | — | — | US | disclosed |
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2004074325-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CANCERS | SALMEDIX, INC (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| US-6323210-B2 | TRANSFERASE INHIBITOR | AGOURON PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | VARNEY MICHAEL D (US) | 2001-08-30 | — | — | US | disclosed |
| US-6207670-B1 | USE TO INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICROORGANISMS SUCH AS BACTERIA, YEAST AND FUNGI | AGOURON PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| EP-0674516-B1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMA (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0674516-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| EP-0674516-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | IMPDH1, IMPDH2, DCK | GART 57/4885FOLR1 767/4885SLC46A1 1503/4885 |
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | GART, GARS1, NUDT1 | GART 1/4885FOLR1 586/4885SLC46A1 538/4885 |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | IMPDH1, IMPDH2, IMPA1 | GART 61/4885FOLR1 551/4885SLC46A1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.